Mortality associated with clozapine: What is the evidence?

Emilio Fernandez-Egea; Robert J. Flanagan; David Taylor; Fiona Gaughran; Stephen M. Lawrie; Christopher Jenkins; Shubulade Smith; Oliver D. Howes; James H. MacCabe

doi:10.1192/bjp.2024.88

Mortality associated with clozapine: What is the evidence?

Emilio Fernandez-Egea^*, Robert J. Flanagan, David Taylor, Fiona Gaughran, Stephen M. Lawrie, Christopher Jenkins, Shubulade Smith, Oliver D. Howes, James H. MacCabe

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

1 Citation (Scopus)

Abstract

While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers mortality, partly by reducing schizophrenia-related suicides, but preventable deaths still occur. Clozapine should be used earlier and more widely, but there should be better monitoring and better management of toxicity.

Original language	English
Pages (from-to)	357-359
Number of pages	3
Journal	British Journal of Psychiatry
Volume	225
Issue number	3
DOIs	https://doi.org/10.1192/bjp.2024.88
Publication status	Published - 1 Sept 2024

Keywords

adverse drug reactions
Clozapine
education and training
mortality
safety

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1192/bjp.2024.88

Cite this

@article{84928073b3f34db6abb99abb85d9d698,

title = "Mortality associated with clozapine: What is the evidence?",

abstract = "While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers mortality, partly by reducing schizophrenia-related suicides, but preventable deaths still occur. Clozapine should be used earlier and more widely, but there should be better monitoring and better management of toxicity.",

keywords = "adverse drug reactions, Clozapine, education and training, mortality, safety",

author = "Emilio Fernandez-Egea and Flanagan, {Robert J.} and David Taylor and Fiona Gaughran and Lawrie, {Stephen M.} and Christopher Jenkins and Shubulade Smith and Howes, {Oliver D.} and MacCabe, {James H.}",

note = "Publisher Copyright: Copyright {\textcopyright} The Author(s), 2024.",

year = "2024",

month = sep,

day = "1",

doi = "10.1192/bjp.2024.88",

language = "English",

volume = "225",

pages = "357--359",

journal = "British Journal of Psychiatry",

issn = "0007-1250",

publisher = "Cambridge University Press",

number = "3",

}

TY - JOUR

T1 - Mortality associated with clozapine

T2 - What is the evidence?

AU - Fernandez-Egea, Emilio

AU - Flanagan, Robert J.

AU - Taylor, David

AU - Gaughran, Fiona

AU - Lawrie, Stephen M.

AU - Jenkins, Christopher

AU - Smith, Shubulade

AU - Howes, Oliver D.

AU - MacCabe, James H.

PY - 2024/9/1

Y1 - 2024/9/1

N2 - While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers mortality, partly by reducing schizophrenia-related suicides, but preventable deaths still occur. Clozapine should be used earlier and more widely, but there should be better monitoring and better management of toxicity.

AB - While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers mortality, partly by reducing schizophrenia-related suicides, but preventable deaths still occur. Clozapine should be used earlier and more widely, but there should be better monitoring and better management of toxicity.

KW - adverse drug reactions

KW - Clozapine

KW - education and training

KW - mortality

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85205982120&partnerID=8YFLogxK

U2 - 10.1192/bjp.2024.88

DO - 10.1192/bjp.2024.88

M3 - Editorial

C2 - 39354861

AN - SCOPUS:85205982120

SN - 0007-1250

VL - 225

SP - 357

EP - 359

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

IS - 3

ER -

Mortality associated with clozapine: What is the evidence?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this